Table 3.
List of topics identified as priorities by one director from round one (secondary list) ordered by round three priority ranks
| |
Round 2 |
Round 3 |
Rank | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Topic | Number of responders |
1 to 3 |
Scores* 4 to 6 |
7 to 9 |
Consensus? | Number of responders |
1 to 3 |
Scores* 4 to 6 |
7 to 9 |
Consensus? | |
| % responders | % responders | ||||||||||
| Surgical trials |
30 |
10.0 |
43.3 |
46.7 |
|
23 |
8.7 |
30.4 |
60.9 |
|
1 |
| Use of routine data |
29 |
17.2 |
41.4 |
41.4 |
|
23 |
8.7 |
39.1 |
52.2 |
|
2 |
| Using previous evidence to inform design |
31 |
25.8 |
41.9 |
32.3 |
|
23 |
13.0 |
43.5 |
43.5 |
|
3 |
| Strategies of trial management |
30 |
23.3 |
43.3 |
33.3 |
|
23 |
17.4 |
47.8 |
34.8 |
|
4 |
| Assessing potential for and effect of attrition bias |
30 |
10.0 |
63.3 |
26.7 |
|
23 |
4.3 |
65.2 |
30.4 |
|
5 |
| Non-drug trials |
30 |
23.3 |
46.7 |
30.0 |
|
22 |
13.6 |
59.1 |
27.3 |
|
6 |
| QALYs for children |
31 |
29.0 |
41.9 |
29.0 |
|
23 |
21.7 |
52.2 |
26.1 |
|
7 |
| Calculating the target difference |
31 |
22.6 |
58.1 |
19.4 |
|
23 |
13.0 |
65.2 |
21.7 |
|
8 |
| Patient and public involvement |
30 |
26.7 |
60.0 |
13.3 |
|
23 |
26.1 |
52.2 |
21.7 |
|
9 |
| Strategies for adverse event reporting |
30 |
30.0 |
50.0 |
20.0 |
|
23 |
21.7 |
60.9 |
17.4 |
|
10 |
| Designs in rare diseases |
31 |
12.9 |
64.5 |
22.6 |
|
23 |
13.0 |
73.9 |
13.0 |
|
11 |
| Studies of diagnosis |
29 |
31.0 |
48.3 |
20.7 |
|
23 |
39.1 |
47.8 |
13.0 |
|
12 |
| Methods to adjust for baseline imbalance |
31 |
32.3 |
51.6 |
16.1 |
|
23 |
47.8 |
39.1 |
13.0 |
|
13 |
| Data modelling |
30 |
26.7 |
56.7 |
16.7 |
|
22 |
31.8 |
59.1 |
9.1 |
|
14 |
| Phase IV studies |
30 |
40.0 |
43.3 |
16.7 |
|
22 |
54.5 |
36.4 |
9.1 |
|
15 |
| Prevention studies |
30 |
20.0 |
60.0 |
20.0 |
|
23 |
17.4 |
73.9 |
8.7 |
|
16 |
| Trial reporting issues |
28 |
39.3 |
50.0 |
10.7 |
|
23 |
26.1 |
65.2 |
8.7 |
|
17 |
| Dose–response studies |
30 |
30.0 |
50.0 |
20.0 |
|
23 |
34.8 |
56.5 |
8.7 |
|
18 |
| Methods to measure pain |
31 |
41.9 |
48.4 |
9.7 |
|
23 |
47.8 |
43.5 |
8.7 |
|
19 |
| Low carbon trials |
30 |
70.0 |
23.3 |
6.7 |
out |
23 |
78.3 |
13.0 |
8.7 |
out |
20 |
| Eligibility criteria |
31 |
58.1 |
35.5 |
6.5 |
|
22 |
63.6 |
31.8 |
4.5 |
|
21 |
| Patient preference designs/issues |
29 |
20.7 |
69.0 |
10.3 |
|
23 |
21.7 |
73.9 |
4.3 |
|
22 |
| Design of paediatric investigation plans |
30 |
46.7 |
43.3 |
10.0 |
|
23 |
56.5 |
39.1 |
4.3 |
|
23 |
| Conflict of interest |
31 |
51.6 |
48.4 |
0.0 |
|
23 |
65.2 |
30.4 |
4.3 |
|
24 |
| Database trials |
30 |
33.3 |
63.3 |
3.3 |
|
23 |
26.1 |
73.9 |
0.0 |
|
25 |
| Crossover trials |
31 |
32.3 |
64.5 |
3.2 |
|
23 |
39.1 |
60.9 |
0.0 |
|
26 |
| Incorporating multiple disease/multiple treatment types into single protocols | 30 | 36.7 | 50.0 | 13.3 | 22 | 59.1 | 40.9 | 0.0 | 27 | ||
*Scores 1 to 3: topic not important; Scores 4 to 6: topic important but not critical; Scores 7 to 9: topic critical.